Please Wait
Applying Filters...
menu
    • menu
    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    DATA COMPILATION
    #PharmaFlow

    Pipeline Prospector March 2026 highlights: Lilly to acquire Centessa for US$ 7.8 bn; Merck buys Terns Pharma for US$ 6.7 bn

    Stock Recap
    #PipelineProspector

    Menu

    Monoammonium Glycyrrhizinate

    ACTIVE PHARMA INGREDIENTS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 69Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    31/03/2026 Maruzen Pharmaceuticals
    Japan
    		 Maruzen Pharmaceutical Co., Ltd. 303MF10177 Monoammonium glycyrrhizinate 2021-12-09 2021-12-09 14703-10 Mukaihigashi-cho, Onomichi City, Hiroshima Prefecture
    31/03/2026 Maruzen Pharmaceuticals
    Japan
    		 Maruzen Pharmaceutical Co., Ltd. 222MF10017 Monoammonium glycyrrhizinate 2010-01-07 2010-01-07 14703-10 Mukaihigashi-cho, Onomichi City, Hiroshima Prefecture
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.